thought leadership
Addressing access challenges for cell and gene therapies in the Asia-Pacific region
Sudha Sundaram, Associate Director | December 15, 2023
In the Asia-Pacific (APAC) region, the demand for cell and gene therapies (CGTs) is increasing but the reimbursement environment for these therapies is still nascent. This update, taken from our expert insights report, summarizes how global access initiatives could offer learnings for the APAC region, such as the importance of advocating for expanding healthcare ecosystem investments to enhance CGT capacity, shifting focus to long-term cost-effectiveness, and increasing innovative public – private partnerships (PPP).
Global access initiatives for cell and gene therapies could offer learnings for the Asia-Pacific region
Four key challenges face manufacturers seeking access for CGT in APAC, and here we summarize the learnings from global initiates that could support access in the region.
1. Complex treatment manufacturing flow and logistics
- Infrastructure to improve manufacturing processes enabled through public-private partnerships
- Optimizing accreditation standards for CGT logistics
2. Complex treatment delivery with continuous patient care and monitoring
- Infrastructure to aid CGT delivery (but barriers still observed in multi-payer healthcare systems)
- Patient registries for long-term monitoring
- Local specialized players involvement to ease treatment delivery hurdles
3. Ultra-high cost of CGT with pre- and post-infusion costs
- Dedicated pathways for advanced therapies to assess value
- Moving beyond short-term budget impact to focus on incremental cost-effectiveness
- To manage costs:
- Financing models based on individual patient data
- Cancer center involvement to manage costs over time
4. Uncertainty with regards to long-term treatment outcomes
- Long-term outcomes-based contracts linked to individual patient outcomes
- Novel financing models involving multiple players to reduce risk
For a deep dive into these challenges and learnings
Read the full report, “Cell and gene therapy market access in the Asia-Pacific region”
Supporting your Policy, Access, Value, and Evidence in the Asia-Pacific region
The expert APAC team at Avalere Health will help you bring out the best in your asset, using our extensive market access and disease area experience.
The APAC region is characterized by its dynamic nature and rapidly evolving markets. These are critical to the future growth plans of our biopharmaceutical clients and we are leading many groundbreaking market access projects in the region.
We’re based in Singapore, experienced, easy to talk to, and we love a challenge. Let us show you why our clients come back to work with us time and again. Contact us.